BRAF anticorps (Center)
-
- Antigène Voir toutes BRAF Anticorps
- BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))
-
Épitope
- Center
-
Reactivité
- Humain, Souris, Rat
-
Hôte
-
Poulet
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp BRAF est non-conjugé
-
Application
- Western Blotting (WB), Enzyme Immunoassay (EIA)
- Réactivité croisée (Details)
- Species reactivity (tested):Human, mouse, rat
- Purification
- Affinity chromatography purified via peptide column
- Immunogène
- 18 amino acid peptide near the center of human B-raf
- Top Product
- Discover our top product BRAF Anticorps primaire
-
-
- Indications d'application
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Concentration
- 1.0 mg/mL
- Buffer
- PBS containing 0.02 % sodium azide
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Conseil sur la manipulation
- Avoid repeated freezing and thawing.
- Stock
- -20 °C
- Stockage commentaire
- Store the antibody (in aliquots) at -20 °C.
-
- Antigène
- BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))
- Abstract
- BRAF Produits
- Synonymes
- anticorps B-RAF1, anticorps BRAF1, anticorps NS7, anticorps RAFB1, anticorps C-RMIL, anticorps RMIL, anticorps B-Raf, anticorps braf1, anticorps rafb1, anticorps b-raf1, anticorps sierrabraf, anticorps BRAF, anticorps 9930012E13Rik, anticorps AA120551, anticorps AA387315, anticorps AA473386, anticorps B-raf, anticorps Braf-2, anticorps Braf2, anticorps C230098H17, anticorps C87398, anticorps D6Ertd631e, anticorps braf, anticorps fc48g01, anticorps wu:fc48g01, anticorps B-Raf proto-oncogene, serine/threonine kinase, anticorps B-Raf proto-oncogene, serine/threonine kinase S homeolog, anticorps Braf transforming gene, anticorps si:dkey-222f8.3, anticorps BRAF, anticorps Braf, anticorps braf.S, anticorps braf, anticorps si:dkey-222f8.3
- Sujet
- B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. Mutations in B-raf have been associated with several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung, leading to speculation on the possibility of B-raf as a therapeutic target for treating cancers. Mutations in this gene have also been associated with cardiofaciocutaneous syndrome (CFCS), a disease characterized by heart defects, mental retardation and a distinctive facial appearance.Synonyms: B-Raf proto-oncogene serine/threonine-protein kinase, BRAF, BRAF1, RAFB1, p94, v-Raf murine sarcoma viral oncogene homolog B1
- ID gène
- 673
- NCBI Accession
- NP_004324
- UniProt
- P15056
- Pathways
- Signalisation MAPK, Signalisation RTK, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy
-